about
Applying the guidelines for pharmacists integrating into primary care teamsOmega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular diseaseReview of the top 5 cardiology studies of 2013-14Single vs Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Implantation: A Systematic ReviewDevelopment of a Pharmacist REferral Program in a primary cARE clinic (PREPARE): A prospective cross-sectional study.Professional use of social media by pharmacistsAn evaluation of teaching physical examination to pharmacists.Review of the top 5 cardiology studies of 2011-12.Reasons for non-use of proven pharmacotherapeutic interventions: systematic review and framework development.Triple antithrombotic therapy in patients with atrial fibrillation who have undergone percutaneous coronary intervention with stent implantation.Adverse drug reactions: The importance of maintaining pharmacovigilancePharmacotherapy of heart failure with preserved ejection fraction.Clozapine-Associated Myocarditis: Case Report and Literature Review.Cardiovascular safety outcomes of new antidiabetic therapies.What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?Primary Prevention of Cardiovascular Disease in Older Adults.Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: A meta-analysis.A Systematic Review of Add-on Pharmacologic Therapy in the Treatment of Resistant Hypertension.Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis.Prescribing by Pharmacist's and Collaborative Care: Are We Ready to Accept the Baton and Get in the Race?One good note.DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics.Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.Review of the top 5 cardiology studies of 2015-16.'The bus analogy': A new analogy to help pharmacy students conceptualize the well-stirred model.Patient-Centred Care through Storytelling.Coenzyme Q10 for statin-associated myalgia.Long-term beta-blocker therapy after myocardial infarction in the reperfusion era: a systematic review.Prevention and management of statin adverse effects: A practical approach for pharmacists.Patient satisfaction with services provided by multidisciplinary anticoagulation clinicsCoenzyme Q10 supplementation in the management of statin-associated myalgiaReview of the top 5 cardiology studies of 2017-18Treatment of chronic noncancer pain in patients on opioid therapy in primary care: A retrospective cohort studyAssessment of atrial fibrillation patients' education needs from patient and clinician perspectives: A qualitative descriptive studyCase report and review of clenbuterol cardiac toxicityPatients' perceptions and use of natural health productsAssessment of Condition and Medication Knowledge Gaps Among Atrial Fibrillation Patients: A Systematic Review and Meta-analysisUse of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists
P50
Q26740324-CA904F57-43A5-4720-9D28-99CD5A04C347Q26747026-64152158-08F5-4500-B35F-2920AF5E5FB0Q26776254-4FD03546-9ECE-405B-B6B7-1601ABB6057DQ26799407-F95A8E5A-CB01-468F-B322-829BD97D4223Q33632523-75F6DADA-4C71-40D2-BC90-D9BB00203D38Q35150120-8D9EB6D9-B209-4EE5-89EC-61BC47251754Q36596679-88D31879-20E2-4A79-B051-E2B12789DFA1Q37073908-36A9764E-9A0B-4A7A-A470-E6461D6B1109Q37782417-5BF98B52-FD9E-433E-A2FC-E0DD708D0E73Q38035268-5950192E-D710-4D0E-A9E3-4FB1CF52827CQ38264124-C64663CA-ABC4-4935-9D11-7CDD45A2661EQ38425861-67722B99-CF79-4A5B-A7EA-955933DEEC28Q38610589-68BC7393-3F95-4ACA-A9EF-BC3658E87A35Q38797105-88422F19-A344-4A03-BDF5-770242B21E14Q38813540-CD4D020C-B881-4F4D-B5D2-83D66584A7FDQ38817550-5441E37E-5325-4557-A0E0-6D05CD8699EAQ38834764-BCBF314C-4733-4C36-8C95-4A0BE3E92369Q38872044-67EF3633-9201-4C2E-81B7-4378650EA993Q38945212-5D11B33E-0D9D-455B-99F0-0BC2141641A0Q39416664-B09D1033-9140-4150-A509-08F129A0ED2FQ41193689-3C282754-BDFB-45E8-BF94-B481359C1C14Q42009291-A5DA6D85-3F34-4348-9841-16F9930855E5Q43506365-E762F2D5-C3BA-44F3-8161-CAE2B2D05875Q46494397-564E34A6-CAE9-4ECE-84BE-E70E63687983Q47578619-73240E31-D6FD-44B7-B6E7-063506DFE89AQ49729138-B6A2B14E-6443-4AC9-8C83-353AEE6953DAQ50113551-0234DFC3-98B4-4749-95D1-FD486556FA88Q51732254-E10868C6-1992-4C7C-BE92-A966D2CB0085Q55154739-86FC9512-E2FA-4514-B363-EE7C00D73038Q86999659-17EBD590-171F-4001-8753-75F3D017C9D1Q88156613-D46EEC50-23BD-4B69-94A9-02CE069E06D5Q89456574-4974F0A0-2DBA-4CA6-B11A-4DA48AB568BAQ89456593-5B403116-F652-4282-B5ED-6FE01E63EAABQ90017540-70B57DF7-9624-46ED-9108-64FD5274BEACQ90467457-8DC34516-E84D-4B6F-B9BA-06878189EB02Q91601505-5D04973E-CBEC-4463-8C8D-C3CE86BBD516Q92093507-4F3C50B5-A45F-4094-8418-DBB99CE8104AQ96303911-D0AAFD9A-8055-4C5F-A6C0-023F6800BB28
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Arden R Barry
@en
Arden R Barry
@nl
type
label
Arden R Barry
@en
Arden R Barry
@nl
prefLabel
Arden R Barry
@en
Arden R Barry
@nl
P31
P496
0000-0002-0287-898X